Related Experiment Video
Updated: May 17, 2026
07:29
Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
Metformin's effect on first-year weight gain: a follow-up study
Sven M Carlsen1, Marit P Martinussen, Eszter Vanky
1Unit for Applied Clinical Research, Institute for Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
Pediatrics
|October 17, 2012
Summary
Metformin use in pregnant women with polycystic ovary syndrome (PCOS) led to less maternal weight gain during pregnancy but more postpartum weight retention. Offspring exposed to metformin were heavier at one year of age.
Area of Science:
- Reproductive Endocrinology
- Maternal-Fetal Medicine
- Pharmacology
Background:
- Polycystic ovary syndrome (PCOS) affects women of reproductive age.
- The effects of metformin on pregnant women with PCOS, specifically regarding maternal weight and offspring growth, are not well understood.
- Investigating metformin's impact is crucial for managing PCOS during pregnancy.
Purpose of the Study:
- To evaluate the long-term effects of metformin on maternal weight changes throughout pregnancy and postpartum in women with PCOS.
- To assess the impact of prenatal metformin exposure on offspring anthropometry and weight up to one year of age.
- To provide insights into the safety and efficacy of metformin in managing PCOS during pregnancy.
Main Methods:
- Follow-up analysis of a randomized controlled trial involving 256 women with PCOS.
- Participants received either metformin (2000 mg daily) or placebo from the first trimester until delivery.
- Maternal weight development and offspring anthropometry were recorded at birth and one year postpartum.
Main Results:
- Metformin group women gained less weight during pregnancy compared to placebo.
- No significant differences in neonatal weight or length were observed between groups.
- One year postpartum, metformin-exposed infants were heavier (10.2 ± 1.2 kg vs 9.7 ± 1.1 kg).
Conclusions:
- Metformin use in pregnant PCOS patients resulted in reduced gestational weight gain but increased postpartum weight retention.
- Children exposed to metformin in utero showed increased weight at one year of age.
- These findings highlight the need for careful monitoring of weight in both mothers and offspring when metformin is used during pregnancy for PCOS.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
01:06Oral Hypoglycemic Agents: Glinides
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
01:16Insulin: Dosing Regimen and Adverse Effects
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...